Work Here?
About Umoja Biopharma
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series C
Total Funding
$353.1M
Headquarters
Seattle, Washington
Founded
2019
Overview
Umoja Biopharma focuses on immunotherapy by reprogramming T cells in the body to target and destroy cancer cells. Unlike traditional methods that modify cells outside the body, Umoja's approach modifies the immune system in vivo, aiming for long-lasting remissions. The company primarily targets patients with solid tumors and blood cancers that have not responded to other treatments. Its business model is based on developing and selling a proprietary CAR T-cell gene therapy platform that is scalable and can treat various cancer stages. By producing off-the-shelf therapies in-house, Umoja can distribute treatments more efficiently than those requiring customization for each patient. The goal is to enhance cancer treatment through effective use of the immune system.
Simplify's Take
What believers are saying
- $100M Series C funding supports clinical development and innovation in oncology.
- Collaboration with Nona Biosciences enhances technological capabilities and accelerates development.
- Participation in major conferences boosts visibility and potential for new partnerships.
What critics are saying
- Competition from Interius BioTherapeutics could challenge Umoja's market position in Europe.
- Strategic shifts under new leadership may disrupt current operations.
- Rapid growth in Colorado's life sciences sector may divert talent and investment.
What makes Umoja Biopharma unique
- Umoja Biopharma reprograms T cells in vivo, unlike traditional ex vivo methods.
- Their CAR T-cell platform is scalable, treating cancers at all stages.
- Off-the-shelf therapies allow efficient production and distribution, reducing customization needs.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$353.1M
Above
Industry Average
Funded Over
3 Rounds
SoftBankIndustry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Commuter Benefits
Phone/Internet Stipend
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 1%2 year growth
↑ 4%Umoja Biopharma announced a $100 million Series C financing to advance its in vivo CAR T cell therapy pipeline. The round was co-led by Double Point Ventures and DCVC Bio, with participation from investors like ARK Invest and SoftBank Vision Fund 2. The funds will support clinical development, including the lead CD22 UB-VV400 program. Campbell Murray, M.D., joins the Board of Directors. This financing highlights Umoja's potential to innovate in oncology and autoimmune treatments.
Umoja Biopharma announces oversubscribed $100 million Series C financing to advance in vivo CAR T pipeline through key oncology clinical milestones.
Seattle, USA- based clinical-stage CART-T therapies developer Umoja Biopharma, today announced the closing of a $100 million Series C financing.
Newsletter Signup - Under Article / In Page"*" indicates required fields Advancements in cancer care have been numerous in recent years, with several chimeric antigen receptor (CAR) gene therapies approved by U.S. and European regulators in the past decade. Now, a U.S. trial of an in vivo off-the-shelf therapy has expanded to Europe, marking the first trial of its kind in the region.The phase 1 trial of INT2104, developed by the U.S.-based Interius BioTherapeutics, was signed off by German regulators to test the therapy on patients with B-cell cancers this week. Interius’ chief executive officer (CEO) Phil Johnson was “thrilled” to widen the study in the European Union (EU). The study in Germany follows the dosing of the first patient in Australia back in October. Global phase 1 trial for Interius BioTherapeutics’ in vivo CAR gene therapy INT2104 The investigational therapy INT2104 is a single dose that is delivered intravenously to patients
Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity.
Umoja Biopharma is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Umoja Biopharma
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series C
Total Funding
$353.1M
Headquarters
Seattle, Washington
Founded
2019
Umoja Biopharma is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today